Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy‐proven histological damage†

Abstract

This retrospective analysis demonstrated that HBeAg-negative CHB patients treated with entecavir responded similarly irrespective of baseline ALT level. However, HBeAg-positive patients with mildly elevated ALT responded less well to treatment with entecavir than did those with ALT greater than 2 x ULN.